A phase 2 trial of imatinib mesylate in patients with recurrent nonresectable chondrosarcomas expressing platelet‐derived growth factor receptor‐α or ‐β

Chondrosarcoma (CS) is a rare and heterogeneous sarcoma in which, after failure of surgery and radiotherapy, chemotherapy plays only a marginal role. Different molecular pathways have been shown to be activated in CS; in particular, both isoforms of platelet‐derived growth factor receptor (PDGFR) are expressed and phosphorylated. These observations prompted investigation of the activity of imatinib mesylate (IM) in patients with advanced CS in a phase 2 trial.

[1]  A. Martins,et al.  Imatinib plus low‐dose doxorubicin in patients with advanced gastrointestinal stromal tumors refractory to high‐dose imatinib , 2010, Cancer.

[2]  A. Llombart‐Bosch,et al.  COX-2 expression in chondrosarcoma: a role for celecoxib treatment? , 2010, European journal of cancer.

[3]  T. van Wezel,et al.  Kinome profiling of chondrosarcoma reveals SRC-pathway activity and dasatinib as option for treatment. , 2009, Cancer research.

[4]  B. Yeap,et al.  Phase II study of high-dose photon/proton radiotherapy in the management of spine sarcomas. , 2009, International journal of radiation oncology, biology, physics.

[5]  S. Knuutila,et al.  Genomic Profiling of Chondrosarcoma: Chromosomal Patterns in Central and Peripheral Tumors , 2009, Clinical Cancer Research.

[6]  J. Fletcher,et al.  Heterogeneity of kinase inhibitor resistance mechanisms in GIST , 2008, The Journal of pathology.

[7]  D. Flieder,et al.  Insulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumors , 2008, Proceedings of the National Academy of Sciences.

[8]  S. Bielack,et al.  Mesenchymal chondrosarcoma of soft tissues and bone in children, adolescents, and young adults , 2008, Cancer.

[9]  H. Gelderblom,et al.  The clinical approach towards chondrosarcoma. , 2008, The oncologist.

[10]  J. Blay,et al.  Complete response to imatinib in relapsing pigmented villonodular synovitis/tenosynovial giant cell tumor (PVNS/TGCT). , 2007, Annals of oncology : official journal of the European Society for Medical Oncology.

[11]  F. Bertoni,et al.  Dedifferentiated chondrosarcomas arising in preexisting osteochondromas. , 2007, The Journal of bone and joint surgery. American volume.

[12]  Haesun Choi,et al.  Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  J. Vermeesch,et al.  Array CGH analysis in primary gastrointestinal stromal tumors: Cytogenetic profile correlates with anatomic site and tumor aggressiveness, irrespective of mutational status , 2007, Genes, chromosomes & cancer.

[14]  P. Casali,et al.  Molecular and Biochemical Analyses of Platelet-Derived Growth Factor Receptor (PDGFR) B, PDGFRA, and KIT Receptors in Chordomas , 2006, Clinical Cancer Research.

[15]  P. Casali,et al.  PDGFRα, PDGFRβ and KIT expression/activation in conventional chondrosarcoma , 2006 .

[16]  A. Cleton-Jansen,et al.  Emerging pathways in the development of chondrosarcoma of bone and implications for targeted treatment. , 2005, The Lancet. Oncology.

[17]  F. Sim,et al.  Dedifferentiated chondrosarcoma: the role of chemotherapy with updated outcomes. , 2004, The Journal of bone and joint surgery. American volume.

[18]  F. Grosso,et al.  Imatinib mesylate in chordoma , 2004, Cancer.

[19]  Daniel Jones.  Anticancer drugs: To the rescue? , 2004, Nature Reviews Drug Discovery.

[20]  J. Eary,et al.  Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[21]  A. D. Van den Abbeele,et al.  Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors. , 2002, The New England journal of medicine.

[22]  A. Chott,et al.  Platelet-Derived Growth Factor-&agr; Receptor Expression Supports the Growth of Conventional Chondrosarcoma and Is Associated With Adverse Outcome , 2001, The American journal of surgical pathology.

[23]  A. Cleton-Jansen,et al.  Up-Regulation of PTHrP and Bcl-2 Expression Characterizes the Progression of Osteochondroma towards Peripheral Chondrosarcoma and Is a Late Event in Central Chondrosarcoma , 2000, Laboratory Investigation.

[24]  M. van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors , 2000, Journal of the National Cancer Institute.

[25]  T. Chen,et al.  Optimal two-stage designs for phase ii clinical trials with differentiation of complete and partial responses , 2000 .

[26]  L. Tanoue,et al.  The National Comprehensive Cancer Network , 1998, Cancer.

[27]  Katherine R. Edwards,et al.  A validation study of an Italian version of the brief pain inventory (Breve questionario per la valutazione del dolore) , 1996, Pain.

[28]  R. Simon,et al.  Optimal two-stage designs for phase II clinical trials. , 1989, Controlled clinical trials.

[29]  K. Markou,et al.  National Comprehensive Cancer Network (NCCN) Head and Neck Cancers NCCN Clinical Practice Guidelines in Oncology . 2010. , 2011 .

[30]  J. Debus,et al.  Carbon ion radiotherapy of skull base chondrosarcomas. , 2007, International journal of radiation oncology, biology, physics.

[31]  P. Casali,et al.  PDGFRalpha, PDGFRbeta and KIT expression/activation in conventional chondrosarcoma. , 2006, The Journal of pathology.

[32]  A. Colevas,et al.  The NCI Common Terminology Criteria for Adverse Events (CTCAE) v 3.0 is the new standard for oncology clinical trials. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[33]  M Van Glabbeke,et al.  New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. , 2000, Journal of the National Cancer Institute.